Abstract
Aims/hypothesis
On the basis of our previous studies, we investigated the possible role of focal adhesion kinase (FAK) in the development of insulin resistance in skeletal muscle, a major organ responsible for insulin-stimulated glucose uptake.
Materials and methods
Insulin-resistant C2C12 skeletal muscle cells were transfected with FAK wild-type or FAK mutant plasmids, knocked down using small interfering RNA (siRNA), and their effects on the levels and activities of insulin-signalling molecules and on glucose uptake were determined.
Results
A significant decrease in tyrosine phosphorylation of FAK in insulin-resistant C2C12 cells was observed. A similar decrease was observed in skeletal muscle obtained from insulin-resistant Sprague–Dawley rats fed a high-fat diet. Increased levels of FAK in insulin-resistant C2C12 skeletal muscle cells increased insulin sensitivity and glucose uptake. These effects were reversed by an increase in the level of kinase activity mutant FAK or suppression of endogenous FAK by siRNA. FAK was also found to interact downstream with insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase C and glycogen synthase kinase 3β, leading to translocation of glucose transporter 4 and resulting in the regulation of glucose uptake.
Conclusions/interpretation
The present study provides strong evidence that the modulation of FAK level regulates the insulin sensitivity of skeletal muscle cells. The results demonstrate a direct role of FAK in insulin-resistant skeletal muscle cells for the first time.
Similar content being viewed by others
Introduction
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and is known to play a key role in integrin signalling [1]. FAK can associate with multiple cellular components, including adhesion-associated proteins and signalling molecules [2]. We have previously reported regulation of myogenesis [3, 4] and cell spreading [5, 6] by FAK as a function of its tyrosine phosphorylation in C2C12 skeletal muscle cells due to insulin stimulation. Bianchi et al. [7] reported the regulation of FAK phosphorylation by glycogen synthase kinase 3β (GSK-3β) during cell spreading and migration. In addition, regulation of FAK phosphorylation by insulin stimulation in non-muscle cells has been reported [8–10]. A regulatory role of FAK in IRS-1 levels [11, 12] and hepatic insulin action [13, 14] has also been reported. Genetic studies have provided evidence for interaction between integrin and insulin signalling [15, 16]. The available literature also focuses on the role of FAK in insulin-mediated effects on the cytoskeleton [10, 17]. Recently, Huang et al. [18] have reported that a reduced level of FAK disrupts insulin action in skeletal muscle. However, the role of FAK in regulating insulin resistance in skeletal muscle, if any, and its possible pathway have not been investigated.
We had previously generated an insulin-resistant skeletal muscle model by differentiating mouse C2C12 cells in the chronic presence of insulin (100 nmol/l) in serum-free medium (MFI) [19–22]. The model was validated using glucose-lowering drugs, including pioglitazone [19], metformin [20] and gliclazide [21]. This model was used in the present study to investigate the role of FAK, if any, under conditions of impaired insulin action.
Materials and methods
Materials
Nutrient Mixture F-12 Ham, MCDB 201 medium and 2-deoxy[3H]glucose (2-DOG) were from Sigma Chemical Company (St Louis, MO, USA). Anti-phospho Akt (Ser473), anti-Akt, anti-phospho (Ser) GSK-3β and anti-GSK-3β antibodies were from Cell Signaling Technology (MA, USA). Anti-FAK, anti-phosphotyrosine, anti-insulin receptor (IR) and anti-IRS-1 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Bovine insulin and anti-GLUT4 (also known as SLC2A2) was purchased from Calbiochem (CA, USA). All other reagents were from Sigma unless attributed otherwise.
Cell culture
C2C12 skeletal muscle cell lines (wild-type and transfectants) were maintained in DMEM supplemented with 15% FCS containing penicillin 100 IU/ml and streptomycin 100 μg/ml in 5% CO2 at 37°C [3]. Cells at 70% confluence were differentiated in an equal mixture of MCDB 201 and Ham’s F-12 medium as described previously [19] in the absence (MF, insulin-sensitive condition) or in the chronic presence of 100 nmol/l insulin (MFI, insulin-resistant condition) for 3 days.
Subcellular fractionation
C2C12 myotubes, pretreated with or without insulin, were washed with ice-cold PBS, scraped into buffer A (mmol/l: HEPES 20, pH 7.4, sucrose 250, EDTA 1, phenylmethylsulphonyl fluoride [PMSF] 2) with 10 μg/ml aprotinin and leupeptin and homogenised for 10 min at 4°C, after which low-density microsome (LDM) and plasma membrane fractions were isolated by differential centrifugation [23]. Protein samples (100 μg) were subjected to SDS-PAGE and western immunoblotting.
Transfection of plasmid vectors
C2C12 cells were stably transfected with FAK wild-type and mutant plasmids as described earlier [22].
siRNA transfection
siRNA oligonucleotides against FAK targeted sequence 5′-TGCAATGGAACGAGTATTAAA-3′ were designed and synthesised by Qiagen GmbH (Hilden, Germany). C2C12 cells were transiently transfected with FAK-specific and non-specific siRNA (400 nmol/l) using RNAifect transfection reagent (Qiagen) in reduced-serum Opti-MEM media (Gibco BRL, Carlsbad, CA, USA) according to the manufacturer’s instructions, with minor modifications.
Preparation of cell lysates
Cells were washed with ice-cold PBS and lysed in lysis buffer (mmol/l: HEPES 50, pH 7.4, NaCl 150, MgCl2 1.5, EGTA 1, sodium pyrophosphate 10, sodium fluoride 50, β-glycerophosphate 50, Na3VO4 1, PMSF 2) with 1% Triton X-100, 10 μg/ml each of leupeptin, aprotonin and soyabean trypsin inhibitor at 4°C for 30 min. Homogenates were centrifuged at 16,000 g for 15 min at 4°C [4]. Protein estimation was performed using the Bicinchoninic Acid Kit (Sigma) according to the manufacturer’s instructions. Equal concentrations of lysates of all the samples were subjected to SDS-PAGE followed by western immunoblotting [3].
Tissue preparation from rats fed a high-fat diet
Male Sprague–Dawley rats (Central Animal Facility, NIPER, India) were divided into two equal groups. One of the groups was fed a normal pellet diet, while the other group was fed a high-fat diet for 4 weeks. The high-fat diet comprised: powdered pellets (364 g), lard (310 g), casein (250 g), cholesterol (10 g), dl-methionine (3 g), Yee-sac powder (1 g), vitamin and mineral mix powder (60 g), sodium chloride (2 g). Biochemical analyses and tolerance tests were performed as described previously [24, 25]. Skeletal muscle from the thigh region was collected, washed with PBS (pH 7.4) and lysed using the lysis buffer as described earlier [4]. The use of animals for the experiments was in compliance with the guidelines of our institutional animal ethics committee.
Phosphatidyl inositol 3-kinase activity
Cells were differentiated under MF and MFI conditions and were stimulated with insulin for 10 min. Cells (500 μg) were lysed and immunoprecipitated for IRS-1 [19]. IRS-1-associated activity of phosphatidyl inositol 3-kinase (PI3K) was determined with the PI3K ELISA Kit (Echelon Biosciences Inc., Salt Lake City, UT, USA) according to the manufacturer’s instructions and as reported previously [26–28].
Glucose uptake assays
Glucose uptake assays were performed using 2-DOG as described earlier [21].
Densitometric analysis
Relative densitometric analyses of the samples were determined using Gel Doc 2000 (Bio-Rad, Hercules, CA, USA) and Quantity One 1-D analysis software (Bio-Rad) by giving an arbitrary value of 1.0 to the respective control samples of each experiment, keeping the background value as 0.
Statistical analysis
The data are expressed as mean±SE. For comparison of two groups, p values were calculated using the two-tailed unpaired Student’s t test. In all the cases p < 0.05 was considered to be statistically significant.
Results
To determine the role of FAK in insulin resistance, if any, C2C12 cells were differentiated under insulin-sensitive (MF) or insulin-resistant (MFI) conditions [19]. Cells were lysed, immunoprecipitated with anti-FAK and subjected to western immunoblotting with anti-phosphotyrosine or anti-FAK antibody (Fig. 1a). FAK tyrosine phosphorylation was found to be reduced by 40.3 ± 0.01% in insulin-resistant cells, with no change in its protein level (Fig. 1a). To determine whether FAK tyrosine phosphorylation is affected in insulin-resistant animals, skeletal muscles were isolated from the high-fat-diet-fed Sprague–Dawley rats [24, 25] and examined for FAK phosphorylation. Rats fed high-fat diets show significant elevations in body weight, plasma insulin, plasma glucose, plasma triacylglycerol and plasma cholesterol levels, resulting in insulin resistance [24, 25]. Skeletal muscle isolated from normal and high-fat-diet-fed Sprague–Dawley rats were immunoprecipitated with anti-FAK and subjected to western immunoblotting with anti-phosphotyrosine or anti-FAK antibody. A decrease (57.5 ± 0.04%) in tyrosine phosphorylation was observed in high-fat-diet-fed Sprague–Dawley rats compared with normal rats (Fig. 1b), with no change in its protein level (Fig. 1b). The data thus confirmed the in vitro findings and strongly emphasised the possible involvement of FAK in skeletal muscle insulin resistance.
The role of FAK could be shown either by generating FAK knockout mice or use specific inhibitors. However, FAK knockout studies could not be performed because of reported embryonic lethality [29, 30] and there is no inhibitor of FAK available [2]. Therefore, to address the issue we undertook several lines of study. We generated the C2C12 cell line, which overexpresses haemagglutinin (HA)-tagged plasmid constructs containing the wild-type gene encoding FAK (C2FAKwt/+) or a mutation in the major autophosphorylation site, tyrosine-397 (Y397F; mutant FAK gene, C2FAKmut/+) (Electronic supplementary material [ESM] Fig. 1). C2FAKwt/+ and C2FAKmut/+ cells showed 52 ± 0.1 and 50 ± 0.1% overexpression of the FAKwt and FAKmut genes, respectively, compared with untransfected cells (Fig. 2a). No significant change in cellular morphology (ESM Fig. 2), growth rates and cell death due to transfection was observed, as shown by Trypan Blue exclusion and the TUNEL (terminal deoxyribonucleotide transferase-mediated dUTP nick end labelling) assay (data not shown).
Transfected cells were then subjected to the MF and MFI conditions and tyrosine phosphorylation of FAK was assayed (Fig. 2b). Under both conditions, tyrosine phosphorylation of C2FAKwt/+ cells increased by 56 ± 0.06 and 42.2 ± 0.03% over their respective controls (Fig. 2b, lane 3 vs lane 1, p < 0.01; lane 4 vs lane 2, p < 0.01). Although tyrosine phosphorylation of FAK in the MFI condition was always less than in the MF condition, insulin-resistant C2FAKwt/+ cells exhibited increased tyrosine phosphorylation, and the level of phosphorylation was similar to that of insulin-sensitive C2FAKwt cells (Fig. 2b, lane 4 vs lane 1). Tyrosine phosphorylation of FAK in C2FAKmut/+ cells under the MF or MFI condition was less (by 29.4 ± 0.06 and 25.8 ± 0.05%, respectively) than in their respective controls (Fig. 2b, lane 5 vs lane 1, p < 0.01; lane 6 vs lane 2, p < 0.05). The data therefore suggest correlation between FAK phosphorylation and insulin resistance.
To assess the functional contribution of altered FAK protein level and/or its activation in the pathogenesis of insulin resistance, glucose uptake was measured in the above-mentioned cell lines cultured under the MF or MFI condition. Insulin-sensitive C2FAKwt/+ cells showed a 40.5 ± 0.48% increase in insulin-stimulated 2-DOG uptake compared with C2FAKwt cells (Fig. 2c, lane 3 vs lane 1, p < 0.01). For detailed data with and without insulin stimulation see ESM Fig. 3. Under insulin-resistant conditions, C2FAKwt/+ cells exhibited increased glucose uptake (28.6 ± 0.61%) compared with C2FAKwt cells (Fig. 2c, lane 4 vs lane 2, p < 0.01), comparable with that observed in insulin-sensitive C2FAKwt cells (Fig. 2c, lane 4 vs lane 1). Cells with increased levels of FAK were thus protected from the development of hyperinsulinaemia-induced insulin resistance. However, C2FAKmut/+ cells developed insulin resistance as there was no insulin-stimulated increase in glucose uptake (Fig. 2c, lane 5 vs lane 1, p < 0.01 and lane 6 vs lane 2, p < 0.01).
To further establish the role of FAK, the siRNA approach was used. Maximum downregulation (84.6 ± 0.01%) of FAK was observed at 400 nmol/l of siRNA (ESM Fig. 4a), specific to FAK (ESM Fig. 4b), without affecting cellular morphology (ESM Fig. 5), viability and growth rate (data not shown). We next studied the effect of FAK downregulation under the MF and MFI conditions with and without insulin stimulation. The level and phosphorylation of FAK in siRNA-transfected cells remained downregulated under all the culture conditions (Fig. 3a, ESM Fig. 6). Next, we examined the effect of FAK silencing on insulin-stimulated glucose uptake in siRNA-transfected cells (C2siRNAFAKwt) differentiated under the MF and MFI conditions (Fig. 3b). Basal and insulin-stimulated glucose uptake were reduced by 52.1 ± 0.23 and 55.2 ± 0.70% in C2siRNAFAKwt cells compared with C2FAKwt cells, respectively (Fig. 3b, lane 5 vs lane 1, p < 0.01; lane 6 vs lane 2, p < 0.01). Similar decreases were observed under the insulin-resistant condition. No change in insulin-stimulated glucose uptake was observed in cells transfected with non-specific siRNA (ESM Fig. 7). siRNA knock-down further supports the idea that elimination of FAK decreases cellular glucose uptake, which might be a consequence of impaired insulin signalling. To further substantiate our results, FAK was silenced in L6E9 cells, which are known to have a greater concentration of glucose transporter than C2C12 cells, and the cells were used in experiments similar to those described above. Basal and insulin-stimulated glucose uptake was both substantially reduced in FAK-silenced L6E9 cells (L6siRNAFAKwt) compared with non-silenced wild-type cells (L6FAKwt) (ESM Fig. 8). The data suggest that the FAK is necessary for insulin-stimulated glucose uptake in L6E9 cells, as observed in the C2C12 cell line.
We next examined the potential molecular mechanisms that might underlie the protection from insulin resistance conferred by an increased level of FAK and corresponding tyrosine phosphorylation. The possible mechanisms include increased insulin-mediated activation of the IR and/or its downstream molecules. Therefore, we examined IR-β tyrosine phosphorylation and production in C2FAKwt, C2FAKwt/+, C2FAKmut/+ and C2siRNAFAKwt cells under the MF and MFI conditions. No significant change in insulin-mediated activation or level of IR-β due to modulation of FAK activation was observed (data not shown).
Previously, FAK was reported to interact with IRS-1 but not with IR [31–33]. Therefore, IRS-1 tyrosine phosphorylation and protein level in C2FAKwt, C2FAKwt/+ and C2FAKmut/+ cells under MF and MFI conditions were examined. C2FAKwt/+ cells in the MF condition showed increased (92.8 ± 0.05%) insulin-stimulated IRS-1 phosphorylation (Fig. 4a, lane 4 vs lane 2, p < 0.01), whereas a decrease (46.4 ± 0.03%) was seen in C2FAKmut/+ cells (Fig. 4a, lane 6 vs lane 2, p < 0.01), in which phosphorylation was similar to that in insulin-resistant C2FAKwt cells (Fig. 4a, lane 6 vs lane 8). C2FAKwt/+ cells under the MFI condition showed an 80.7 ± 0.03% increase in insulin-stimulated IRS-1 tyrosine phosphorylation (Fig. 4a, lane 10 vs lane 8, p < 0.01), and the level of phosphorylation was similar to that in C2FAKwt cells (Fig. 4a, lane 10 vs lane 2), whereas it decreased (by 24.9 ± 0.01%) in C2FAKmut/+ cells (Fig. 4a, lane 12 vs lane 8, p < 0.01). No significant change was observed in the level of IRS-1. To confirm these results, IRS-1 tyrosine phosphorylation was measured in C2siRNAFAKwt cells. Decreases in insulin-stimulated IRS-1 phosphorylation of 71.0 ± 0.02% in the MF condition and 41.5 ± 0.02% in the MFI condition (Fig. 4b, lane 6 vs lane 2, p < 0.01; lane 8 vs lane 4, p < 0.01) were observed; these results were similar to those observed in C2FAKmut/+ cells. The data therefore suggest that at least one of the ways in which FAK regulates insulin resistance in C2C12 skeletal muscle is through IRS-1 tyrosine phosphorylation. FAK functions upstream of IRS-1, as inhibition of FAK abrogates IRS-1 phosphorylation.
To explore the role(s) of FAK in regulating downstream molecules, IRS-1-associated PI3K activity was determined. In C2FAKwt/+ cells, insulin-stimulated PI3K activity increased 1.7 ± 0.29-fold in the MF condition (Fig. 4c, lane 4 vs lane 2, p < 0.01), whereas it decreased 2.18 ± 0.08-fold in C2FAKmut/+ cells (Fig. 4c, lane 6 vs lane 2, p < 0.01), and in the mutant cells the PI3K activity was same as that of insulin-resistant C2FAKwt cells (Fig. 4c, lane 6 vs lane 8). C2FAKwt/+ cells under the MFI condition showed a 3.6 ± 0.25-fold increase in PI3K activity (Fig. 4c lane 10 vs lane 8, p < 0.01), and the extent of activation was same as that of insulin-sensitive C2FAKwt cells (Fig. 4c, lane 10 vs lane 2). Insulin-stimulated IRS-1-associated PI3K activity was unaltered in C2FAKmut/+ cells under the MFI condition (Fig. 4c, lane 12 vs lane 11), but decreased 4.4 ± 0.01-fold and 1.2 ± 0.01-fold under the MF and MFI conditions, respectively (Fig. 4d, lane 6 vs lane 2, p < 0.01; lane 8 vs lane 4, p < 0.01) in C2siRNAFAKwt cells.
PI3K activates several PIP3-dependent serine/threonine kinases, e.g. Akt (also known as protein kinase B [PKB]) and protein kinase C (PKC) [34, 35]. Therefore, insulin-stimulated activation, if any, of Akt was examined in all the cell lines (Fig. 4e). No additional insulin-stimulated effect of Akt phosphorylation (Ser473) was observed in C2FAKwt/+ cells (Fig. 4e, lane 4 vs lane 2). This may have been due to saturable activation of Akt. Although under the insulin-resistant condition C2FAKwt/+ cells showed additional insulin-stimulated Akt phosphorylation, the extent of activation was not equivalent to that seen in insulin-sensitive C2FAKwt cells (Fig. 4e, lane 10 vs lane 2). C2FAKmut/+ cells displayed decreased Akt activation in both the MF and the MFI condition (Fig. 4e, lane 6 vs lane 2, p < 0.01; lane 12 vs lane 8, p < 0.01). Similar decreases were observed in C2siRNAFAKwt cells (66.2 ± 0.2 and 58 ± 0.13% in the MF and MFI conditions, respectively) (Fig. 4f, lane 6 vs lane 2, p < 0.01; lane 8 vs lane 4, p < 0.01). This indicates possible signal divergence under the insulin-resistant condition.
PKC is reported to regulate glucose uptake downstream of PI3K [34, 35]. Therefore, insulin-stimulated activation of PKC, if any, was tested in all the cell lines by probing with anti-phospho pan-PKC antibody. Insulin-stimulated PKC phosphorylation of C2FAKwt/+ cells increased (by 21.4 ± 0.05%) under the MF condition (Fig. 4g, lane 4 vs lane 2, p < 0.01) but decreased (by 37.4 ± 0.03%) in C2FAKmut/+ cells (Fig. 4g, lane 6 vs lane 2, p < 0.01), and the level of activation was similar to that in insulin-resistant C2FAKwt cells (Fig. 4g, lane 6 vs lane 8). Insulin-stimulated PKC phosphorylation increased (76.3 ± 0.03%) in C2FAKwt/+ cells under the MFI condition (Fig. 4g, lane 10 vs lane 8, p < 0.01), and the extent of activation was as observed in insulin-sensitive C2FAKwt cells (Fig. 4g, lane 10 vs lane 2), whereas it was further decreased (37.5 ± 0.01%) in C2FAKmut/+ cells (Fig. 4g, lane 12 vs lane 8, p < 0.01) without affecting its protein level (Fig. 4g). PKC phosphorylation of C2siRNAFAKwt cells decreased by 62.6 ± 0.02 and 56 ± 0.01% under the MF and MFI conditions, respectively (Fig. 4h, lane 6 vs lane 2, p < 0.01 and lane 8 vs lane 4, p < 0.01) without altering the protein level. The data confirm the involvement of PKC and suggest its possible involvement in signal divergence in FAK-mediated insulin signalling.
To evaluate the contribution of PKC to glucose uptake, we downregulated the level of PKC by differentiating C2FAKwt, C2FAKwt/+ and C2FAKmut/+ cells under prolonged exposure (3 days) to 100 nmol/l phorbol 12,13-dibutyrate (PDBu) [4, 36]. PKC protein level (Fig. 5a) and phosphorylation (Fig. 5b) were completely inhibited under all the conditions examined. A significant decrease in insulin-stimulated glucose uptake was observed in all the cell lines treated with PDBu (Fig. 5c). Similar effects on PKC level/phosphorylation (Fig. 5d,e) and glucose uptake (Fig. 5f) were observed in C2siRNAFAKwt cells treated with PDBu. The data suggest that PKC is the downstream molecule responsible for FAK-mediated glucose uptake.
FAK was previously reported to regulate the activity of GSK-3β (a regulatory enzyme upstream of glycogen synthase) in hepatocytes, [7, 13]. To determine whether the observed effect of an increased level of FAK was accompanied by GSK-3β activation, insulin-stimulated Ser-9 phosphorylation of GSK-3β was examined. C2FAKwt/+ cells increased insulin-stimulated GSK-3β phosphorylation under the MF condition (by 27.8 ± 0.05%; Fig. 6a, lane 4 vs lane 2, p < 0.01), whereas phosphorylation was decreased in C2FAKmut/+ cells (by 32.4 ± 0.03%; Fig. 6a, lane 6 vs lane 2, p < 0.01) compared with insulin-resistant C2FAKwt cells (Fig. 6a, lane 6 vs lane 8). C2FAKwt/+ cells showed increased (by 49.3 ± 0.03%) GSK-3β phosphorylation under the MFI condition (Fig. 6a, lane 10 vs lane 8, p < 0.01), and the level of phosphorylation was similar to that observed in insulin-sensitive C2FAKwt cells (Fig. 6a, lane 10 vs lane 2), whereas it was further decreased (by 21.5 ± 0.01%) in C2FAKmut/+ cells (Fig. 6a, lane 12 vs lane 8, p < 0.01). An acute decrease in GSK-3β phosphorylation was observed in C2siRNAFAKwt cells under the MF and MFI conditions (Fig. 6b, lane 6 vs lane 2, p < 0.01 and lane 8 vs lane 4, p < 0.01). No change in GSK-3β level was observed under any condition. The data suggest anabolism between enhanced glucose uptake and glycogen synthesis as a result of increased GSK-3β phosphorylation due to FAK overproduction.
Since no change in the level of GLUT4 was observed in any of the cell lines under any condition (Fig. 7a,b), insulin-stimulated translocation of GLUT4 was examined in subcellular fractions (LDM and plasma membrane). We observed a 32.0 ± 0.12% increase in GLUT4 translocation to the plasma membrane fraction of C2FAKwt/+ cells under the MF condition (Fig. 7c, lanes 7 and 8 vs lanes 3 and 4), indicating enhanced insulin-stimulated GLUT4 translocation due to an increased level of FAK. In contrast, GLUT4 molecules remained in the LDM fraction in insulin-sensitive C2FAKmut/+ cells (Fig. 7c, lanes 9 and 10 vs lanes 1 and 2). Under the MFI condition, maximum translocation was observed in C2FAKwt/+ cells (Fig. 7d, lanes 7 and 8 vs lanes 3 and 4) and almost no translocation was observed in C2FAKmut/+ cells (Fig. 7d, lanes 11 and 12 vs lanes 1 and 2). Insulin-stimulated incremental GLUT4 translocation was significantly impaired in C2siRNAFAKwt cells compared with C2FAKwt. In contrast to C2FAKwt cells, the maximum number of GLUT4 molecules in C2siRNAFAKwt cells remained in the LDM fraction under the MF as well as under the MFI condition (Fig. 7e, lane 5 vs lane 1 and lane 7 vs lane 3). However, in the plasma membrane fraction there was a significant decrease in the translocation of GLUT4 in C2siRNAFAKwt cells compared with C2FAKwt cells, which was further decreased under the MFI condition (Fig. 7e, lane 6 vs lane 2 and lane 8 vs lane 4). These results confirm the regulation of glucose uptake via GLUT4 translocation in skeletal muscle cells in vitro by FAK.
Discussion
In the present study a direct correlation was observed between FAK protein level/phosphorylation and glucose uptake in the presence of insulin, suggesting insulin-dependent regulation of insulin resistance in C2C12 skeletal muscle cells by FAK. Huang et al. [18] reported that downregulation of FAK affects only insulin-stimulated glucose uptake, unlike the observations in our study (Fig. 3b). One of the possible explanations for this could be that Huang et al. reported glucose uptake when there was 53% downregulation in the level of FAK, leaving approximately 47% of the endogenous FAK available, whereas in our study 85% of the FAK was downregulated, thus eliminating any significant contribution of the endogenous protein. Under our experimental conditions, the mechanism of FAK-mediated regulation of insulin resistance could be the interaction of FAK with unidentified substrate(s) that becomes activated only in the presence of insulin and is necessary for the interaction between FAK and insulin signalling molecules. The observed increase in tyrosine phosphorylation in the basal condition of overexpressed FAK might be due to activation by other stimuli.
Like us, Annabi et al. [31] and Huang et al. [14] also observed no interaction between FAK and the IR in their studies, using CHO and HepG2 cells. However, we observed that up- or downregulation of FAK activity correspondingly affected insulin-stimulated glucose uptake via the IRS-1/PI3K pathway. Therefore, our results indicate that FAK regulates insulin signalling upstream of IRS-1 and then regulates the cascade downstream via PI3K. Insulin signalling without involving the IR, via IRS-1, has been reported previously in other non-receptor tyrosine kinases, pp59Lyn in 3T3-adipocytes [37]. FAK is also reported to interact with cytosolic tyrosine kinase Src, which can regulate IRS-1 tyrosine phosphorylation in CHO cells [33]. In human embryo kidney cells, Lebrun et al. [33] have reported that FAK can phosphorylate IRS-1 without the participation of Src.
In our study, the mechanism whereby mutant FAK inhibits the ability of insulin to induce phosphorylation of Akt remains unclear. It is possible that endogenous FAK interacts with unidentified protein(s) necessary for interaction with Akt. Mutant FAK possibly exerts a dominant negative effect on endogenous FAK. A similar dissociation between these two proteins has been reported previously in hepatocytes [14]. However, an increased level of FAKwt did not restore Akt phosphorylation under insulin-resistant conditions even though tyrosine phosphorylation of IRS-1 and PI3K activation was restored. A possible explanation includes additional regulation of Akt independently of PI3K in the insulin-resistant condition. Lin et al. [38] found that PKC activator decreased the ability of insulin to phosphorylate both Akt and GSK-3β in rat skeletal muscle, whereas PI3K activation was unaffected.
Decreased glucose uptake irrespective of an increased or decreased level of FAK under conditions of PKC inhibition indicates a markedly smaller contribution of Akt. Therefore, in the insulin-resistant condition the signal travels mainly through activated PI3K to PKC rather than to Akt. Earlier reports have suggested that phosphatidylinositol (3,4,5)-triphosphate (PIP3) produced by PI3K, responsible for both Akt and PKC phosphorylation, has more affinity for PKC than Akt [34]. Moreover, in the insulin-resistant condition PKC downregulates Akt and this is unaccompanied by a change in PI3K activity in skeletal muscle cells [37]. Therefore, it is possible that FAK differentially regulates insulin signalling under normal and insulin-resistant conditions. Sajan et al. [39] recently reported a differential role of the atypical PKC isoforms ζ and λ in insulin-stimulated glucose transport. Regulation of GLUT4 translocation in skeletal muscle of high-fat-diet-fed rats by PKC (ζ/λ) has also been reported [40]. Therefore, there is a possibility of FAK-regulated activity of PKC ζ/λ, or any other isoform(s), in regulating insulin resistance. Further studies are in progress to determine the specific isoform(s) that may be responsible for interacting with FAK to regulate the pathway.
It has been reported that modulation of FAK level in hepatocytes regulates glycogen synthesis [7, 14]. We also observed that up- or downregulation of FAK correspondingly phosphorylates GSK-3β, implying the regulation of glycogen synthesis by FAK in these cells.
Kotliar and Pilch [41] observed that the increased level of GLUT4 fails to reconstitute insulin-stimulated glucose transporter in C2C12 cells and postulated the requirement for additional gene(s) to form functional translocating vesicles. Microtubules have been reported to be required for the translocation of GLUT4 [18, 42–46]. FAK is required for the stabilisation of microtubules in fibroblasts [47] and its tyrosine phosphorylation is essential for the insulin-stimulated rearrangement of actin fibres in CHO/IR cells [10]. Huang et al. [18] reported that FAK regulates insulin-mediated cytoskeletal rearrangement essential for normal glucose transport and glycogen synthesis. Therefore, the observed increase in glucose uptake as a result of increased FAK level with no change in expression in our study is possibly due to the enhanced recruitment of actin filament and microtubules responsible for the GLUT4 translocation. Further studies are in progress to demonstrate interaction between GLUT, microtubules and FAK.
In summary, the present study demonstrates a novel role for FAK as a positive regulator of the insulin signalling pathway, leading to glucose transport and insulin sensitisation. This conclusion is based on the following findings: (1) in the insulin-resistant condition FAK was always found to be less active; (2) downregulation of FAK activity resulted in impaired insulin signalling; (3) decreased glucose uptake was a consequence of impaired insulin signalling due to downregulation of FAK; and (4) increased level of FAK in the insulin-resistant condition reversed all the above-mentioned observations. The stimulatory effect of FAK on insulin-stimulated glucose transport involves the IRS-1/PI3K/PKC arm of the insulin signalling pathway. Interestingly, IR and Akt do not seem to contribute to the pathway. Since an increase in FAK and its phosphorylation sensitises C2C12 skeletal muscle cells to insulin stimulation of GLUT4 translocation and glucose transport, these results further support a role for an insulin-stimulated FAK/IRS-1/PI3K/PKC signalling pathway as a physiologically important mediator of the action of insulin. Since increased levels of FAK leads to cellular insulin sensitisation, these results also raise the possibility that interfering with FAK production or activation may provide opportunities for developing new therapeutic strategies against insulin resistance. Chemical activators of FAK would be expected to act as insulin sensitisers, which could have beneficial effects in insulin resistance induced by hyperinsulinaemia. This opens up the possibility of new therapeutic intervention.
Abbreviations
- 2-DOG:
-
2-deoxy[3H]glucose
- FAK:
-
focal adhesion kinase
- GSK-3β:
-
glycogen synthase kinase 3β
- IR:
-
insulin receptor
- LDM:
-
low-density microsome
- MF:
-
MCDB 201:Ham’s F-12 serum-free medium (1:1)
- MFI:
-
MCDB 201:Ham’s F-12 serum-free medium with insulin (1:1)
- PDBu:
-
phorbol 12,13-dibutyrate
- PI3K:
-
phosphatidyl inositol 3-kinase
- PMSF:
-
phenylmethylsulphonyl fluoride
- PKC:
-
protein kinase C
- siRNA:
-
small interfering RNA
References
Parson JT (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116:1409–1416
Zachary I (1997) Focal adhesion kinase. Int J Biochem Cell Biol 29:929–934
Goel HL, Dey CS (2002) Focal adhesion kinase tyrosine phosphorylation is associated with myogenesis and modulated by insulin. Cell Prolif 35:131–142
Goel HL, Dey CS (2000) PKC-regulated myogenesis is associated with increase in phosphorylation of FAK, cas and paxillin, formation of cas-crk complex and JNK activation. Differentiation 70:257–271
Goel HL, Dey CS (2002) Insulin stimulates spreading of skeletal muscle cells involving the activation of focal adhesion kinase, phosphatidylinositol 3-kinase and extracellular signal regulated kinase. J Cell Physiol 193:187–198
Goel HL, Dey CS (2002) Role of protein kinase C during insulin mediated skeletal muscle cell spreading. J Muscle Res Cell Motil 23:269–277
Bianchi M, De Lucchini S, Marin O, Turner DL, Hanks SK, Villa-Moruzzi E (2005) Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration. Biochem J 391:359–370
Baron V, Calleja V, Ferrari P, Alengrin F, van Obberghen E (1998) p125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors. J Biol Chem 273:162–7168
Tobe K, Sabe H, Yamamoto T et al (1996) Csk enhances insulin-stimulated dephosphorylation of focal adhesion proteins. Mol Cell Biol 16:4765–4772
Knight JB, Yamauchi K, Pessin JE (1995) Divergent insulin and platelet-derived growth factor regulation of focal adhesion kinase (pp125FAK) tyrosine phosphorylation and rearrangement of actin stress fibers. J Biol Chem 270:10199–10203
Yujiri T, Nawata R, Takahashi T, Sato Y, Tanizawa Y, Kitamura T, Oka Y (2003) MEK kinase interacts with focal adhesion kinase and regulates insulin receptor substrate-1 expression. J Biol Chem 278:3846–3851
Wang Q, Bilan PJ, Klip A (1998) Opposite effects of insulin on focal adhesion proteins in 3T3-L1 adipocytes and in cells overexpressing the insulin receptor. Mol Biol Cell 9:3057–3069
Cheung AT, Wang J, Ree D, Kolls JK, Bryer-Ash M (2000) Tumor necrosis factor α induces hepatic insulin resistance in obese zucker (fa/fa) rats via interaction of leukocyte antigen related tyrosine phosphatase with focal adhesion kinase. Diabetes 49:810–819
Huang D, Cheung AT, Parsons JT, Bryer-Ash M (2002) Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes. J Biol Chem 227:18151–18160
Guilherme A, Torres K, Czech MP (1998) Cross-talk between insulin receptor and integrin α5β1 signaling pathways. J Biol Chem 273:22899–22903
Eliceiri BP (2001) Integrins and growth factor receptor crosstalk. Circ Res 89:1104–1110
Turner CE (2000) Paxillin and focal adhesion signaling. Nat Cell Biol 2:E231–E236
Huang D, Kohe M, Ilic D, Bryer-Ash M (2006) Reduced expression of focal adhesion kinase disrupts insulin action in skeletal muscle cells. Endocrinology 147:3333–3343
Kumar N, Dey CS (2003) Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. Biochem Pharmacol 65:249–257
Kumar N, Dey CS (2002) Metformin enhances insulin signaling in insulin-dependent and -independent pathways in insulin-resistant muscle cells. Br J Pharmacol 137:329–336
Kumar N, Dey CS (2002) Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. J Exp Biol 205:3739–3746
Verma NK, Singh J, Dey CS (2004) PPAR-γ expression modulates insulin sensitivity in C2C12 skeletal muscle cells. Br J Pharmacol 143:1006–1013
Michael LF, Wu Z, Cheatham RB et al (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA 98:3820–3825
Srinivasan K, Patole PS, Ramarao P (2004) Reversal of glucose intolerance by pioglitazone in high fat diet fed rats. Methods Find Exp Clin Pharmacol 26:327–333
Ghatta S, Ramarao P (2004) Increased contractile responses to 5-hydroxytrypamine and angiotensin II in high fat diet fed rat thoracic aorta. Lipids Health Dis 3:1–6
Sentinelli F, Filippi E, Cavallo MG, Romeo S, Fanelli M, Baroni MG (2006) The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes: treatment with a PPARgamma agonist restores normal cell signaling and differentiation. J Endocrinol 188:271–285
Kobayashi T, Hayashi Y, Taguchi K, Matsumoto T, Kamata K (2006) ANG II enhances contractile responses via PI3-kinase p110b pathway in aortas from diabetic rats with systemic hyperinsulinemia. Am J Physiol Heart Circ Physiol 291:H846–H853
Verma NK, Dey CS (2006) Anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Diabetologia 49:1656–1660
Schaller MD (2001) Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 1540:1–21
Ilic D, Kovacic B, Johkura K et al (2004) FAK promotes organization of fibronectin matrix and fibrillar adhesions. J Cell Sci 117:177–187
Annabi SE, Gautier N, Baron V (2001) Focal adhesion kinase and Src mediate integrin regulation of insulin receptor phosphorylation. FEBS Lett 507:247–252
Lebrun P, Baron V, Hauck CR, Schlaepfer DD, Obberghen EV (2000) Cell adhesion and focal adhesion kinase regulates insulin receptor substrate-1 expression. J Biol Chem 275:38371–38377
Lebrun P, Mothe-Satney I, Delahaye L, Obberghen EV, Baron V (1998) Insulin receptor substrate-1 as a signaling molecule for focal adhesion kinase pp125FAK and pp60src. J Biol Chem 273:32244–32253
Farese VR (2002) Function and dysfunction of aPKC isoforms for glucose transport in insulin-sensitive and insulin-resistant states. Am J Physiol Endocrinol Metab 283:E1–E11
Hirai T, Chida K (2003) Protein kinase C: activation mechanisms and cellular functions. J Biochem 133:1–7
Webb BLJ, Hirst SJ, Giembycz MA (2000) Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis. Br J Pharmacol 130:1433–1452
Muller G, Wied S, Frick W (2000) Cross talk of pp125FAK and pp59Lyn nonreceptor tyrosine kinase to insulin-mimetic signaling in adipocytes. Mol Cell Biol 20:4708–4723
Lin YS, Itani SI, Kurowski TG et al (2001) Inhibition of insulin signaling and glycogen synthesis by phorbol dibutyrate in rat skeletal muscle. Am J Physiol Endocrinol Metab 281:E8–E15
Sajan MP, Rivas J, Li P, Standaert ML, Farese RV (2006) Repletion of atypical protein kinase C following RNAi-mediated depletion restores insulin-stimulated glucose transport. J Biol Chem 281:17466–17473
Tremblay F, Lavigne C, Jacques H, Marette A (2001) Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinase C (ζ/λ) activities. Diabetes 50:1901–1910
Kotliar N, Pilch PF (1992) Expression of the glucose transporter isoform GLUT4 is insufficient to confer insulin regulatable hexose uptake to cultured muscle cells. Mol Endocrinol 6:337–345
Olson AL, Trumbly AR, Gibson GV (2001) Insulin-mediated GLUT4 translocation is dependent on the microtubule network. J Biol Chem 276:10706–10714
Liu LB, Omata W, Kojima I, Shibata H (2003) Insulin recruits GLUT4 from distinct compartments via distinct traffic pathways with differential microtubules dependence in rat adipocytes. J Biol Chem 278:30157–30169
Fletcher LM, Welsh GI, Oatey PB, Tavare JM (2000) Role for the microtubule cytoskeleton in GLUT4 vesicle trafficking and in the regulation of insulin- stimulated glucose uptake. Biochem J 352:267–276
Olson AL, Eyster CA, Duggins QS, Knight JB (2003) Insulin promotes formation of polymerised microtubules by a phosphatidylinositol 3-kinase-independent, actin-dependent pathway in 3T3-L1 adipocytes. Endocrinology 144:5030–5039
Patel N, Rudich A, Khayat ZA, Garg R, Klip A (2003) Intracellular segregation of phosphatidylinositol-3,4,5-trisphosphate by insulin-dependent actin remodeling in L6 skeletal muscle cells. Mol Cell Biol 23:4611–4626
Palazzo AF, Eng CH, Schlaepfer DD, Maracantonio EE, Gundersen GG (2004) Localized stabilization of microtubules by integrin- and FAK-Facilitated Rho signaling. Science 303:836–839
Acknowledgements
We thank C. L. Kaul, formerly director of NIPER, for his keen interest in this study. We also thank P. Ramarao, director of NIPER and head of the Pharmacology Department, for providing us with rat muscle samples. We gratefully acknowledge D. Schlaepfer of the Scripps Research Institute, La Jolla, CA, USA for providing pcDNA3.1-HA-FAKwt and pcDNA3.1-HA-FAKmut plasmids as a kind gift. R. Singh is acknowledged for his assistance in the laboratory. B. Bisht is the recipient of a Senior Research Fellowship and H. L. Goel was the recipient of a Senior Research Fellowship from the Council of Scientific and Industrial Research, Government of India, New Delhi. This study was also supported by a grant from the Department of Biotechnology, Government of India, New Delhi to C. S. Dey (BT/HRD/34/04/2004, dated 30.4.2004; BT/PR3994/MED/14/498/2003, dated 30 September 2004).
Author information
Authors and Affiliations
Corresponding author
Additional information
Niper communication no. 389
Electronic supplementary material
Authors’ contributions
B. Bisht designed and executed most of the experiments involving biochemistry, cell biology, molecular biology, western imunoblotting, immunoprecipitation, microscopy, recombinant DNA technology, siRNA transfections, organised and analysed data and drafted the initial manuscript. H. L. Goel demonstrated FAK tyrosine phosphorylation through immunoprecipitation and western immunoblotting under insulin-resistant condition. C. S. Dey conceived the study, designed and coordinated experiments, analysed the data, wrote and finalised the manuscript.
Below is the link to the electronic supplementary material.
ESM Fig. 1
Stable transfection of FAKwt/FAKmut gene in C2C12 skeletal muscle cells. C2C12 cells were transfected with HA-tagged FAKwt and FAKmut containing vector pCDNA3.1. Cell lysates (30 μg each) were analysed for HA to test the expression of HA-tagged genes by western immunoblotting, and probed with anti-HA antibody. IB, immunoblotted (GIF 28 kb)
ESM Fig. 2
Phase-contrast images of a proliferated cells and b differentiated cells. Transfected and untransfected cells were allowed to proliferate and differentiate and cellular morphology was observed using phase-contrast microscopy (GIF 203 kb)
ESM Fig. 3
Effect of modulation of FAK level on glucose uptake. Cells differentiated in serum-free medium in the absence (MF) or chronic presence (MFI) of insulin for 3(days were stimulated with (+) or without (−) 100 nmol/l insulin for 15 min. Uptake of 2-DOG was measured in 40 μg cell lysates. Experiments were repeated three times. Values are mean±SE. *p < 0.05, **p < 0.01 compared with lane 1; ##p < 0.01 compared with lane 2. Open bars, MF; filled bars, MFI (GIF 9 kb)
ESM Fig. 4
a Standardisation of siRNA concentration for knock-down of FAK level. siRNA oligonucleotides (100–400 nmol/l) against FAK were transfected into C2C12 cells. After transfection, cells were allowed to differentiate in MF medium and were lysed, subjected to western immunoblotting and probed with anti-FAK antibody. Graph represents production of FAK in cells transfected with different concentrations of siRNA. Lane 1, control untransfected C2C12 cells; lane 2, 100 nmol/l; lane 3, 200 nmol/l; lane 4, 300 nmol/l; lane 5, 400 nmol/l of FAK siRNA. Experiments were repeated three times. Values are mean±SE. **p < 0.01 compared with lane 1; *p < 0.05 compared with lane 1. a Determination of siRNA specificity. C2C12 myoblasts were transfected with FAK targeted and non-specific siRNA (400 nmol/l) and were allowed to differentiate for 3 days in MF medium. Myotubes were lysed, subjected to western immunoblotting and probed with anti-FAK antibody. Blots were stripped and again probed with anti-actin antibody for determination of equal loading. Bars represent relative densitometric values of FAK level. Lane 1, untransfected cells; lane 2, non-specific siRNA (400 nmol/l); lane 3, cells transfected with FAK siRNA. Experiments were repeated three times. Values are mean±SE. **p < 0.01 compared with lane 1 (GIF 20 kb)
ESM Fig. 5
Phase-contrast images of a proliferated cells and b differentiated cells. siRNA-transfected and untransfected cells were allowed to proliferate and differentiate and their cellular morphology was observed using phase-contrast microscopy (GIF 197 kb)
ESM Fig. 6
Effect of FAK downregulation on its tyrosine phosphorylation. siRNA transfected and untransfected cells were differentiated in serum-free medium in the absence (MF) or chronic presence (MFI) of 100 nmol/l insulin for 3 days. Protein extracts (200 μg each) were immunoprecipitated with anti-FAK antibody, subjected to western immunoblotting and probed with anti-phosphotyrosine or anti-FAK antibody (GIF 19 kb)
ESM Fig. 7
Effect of transfection of non-specific siRNA on glucose uptake. Cells untransfected and transfected with non-specific siRNA were differentiated in serum-free medium in the absence (MF) for 3 days and were stimulated with (+) or without (−) 100 nmol/l insulin for 15 min. Uptake of 2-DOG was measured in 40 μg cell lysates. Experiments were repeated three times. Values are mean±SE. **p < 0.01 compared with lane 1. Open bars, untransfected cells; closed bars, cells transfected with non-specific siRNA (GIF 12 kb)
ESM Fig. 8
Effect of FAK downregulation on L6E9 cells. L6E9 myoblasts were transfected with FAK-targeted siRNA (400 nmol/l) and allowed to differentiate in DMEM medium containing 2% horse serum. a Myotubes were lysed, subjected to western immunoblotting and probed with anti-FAK antibody. Blots were stripped and again probed with anti-actin antibody for the determination of equal loading. Bar represents relative densitometric values of FAK level. b Myotubes were incubated in serum- and glucose-deprived buffer for 4 h. Uptake of 2-DOG was measured in 40 μg cell lysates. Uptake was measured in duplicate. Data are shown as pmol mg−1 min−1. Lanes 1 and 2, untransfected cells; lanes 3 and 4, cells transfected with FAK siRNA (400 nmol/l). Experiments were repeated three times. Values are mean±SE. **p < 0.01 compared with lane 1.Open bars, untransfected cells; filled bars, cells transfected with siRNA (GIF 39 kb)
Rights and permissions
About this article
Cite this article
Bisht, B., Goel, H.L. & Dey, C.S. Focal adhesion kinase regulates insulin resistance in skeletal muscle. Diabetologia 50, 1058–1069 (2007). https://doi.org/10.1007/s00125-007-0591-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-007-0591-6